Videos

Common scenarios for which genomic testing is recommended to aid in treatment decisions for patients with hormone receptor-positive breast cancer.

Lee Schwartzberg, MD, FACP, of West Cancer Center & Research Institute, discusses the role of genomic testing in hormone receptor-positive breast cancer and compares information provided by various assays approved for use.

Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.

A specialist explains the factors considered when it comes to choosing treatments for patients with relapsed/refractory follicular lymphoma, and the clinical endpoints to look for.

Javier L. Munoz, MD, MS, FACP, describes the effects of R/R FL and discusses the current treatment options available.

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

Agha emphasized that the annual conference allows investigators to set the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

Stephanie White, DO, and Preeti Kotha, PharmD, detailed their experiences running the WesternU Health Clinic COVID-19 vaccine program from when vaccines were first approved in the United States until now.

Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.

Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, to discuss recent updates in the treatment of gastrointestinal malignancies.

CancerNetwork® sat down with Salma Jabbour, MD, of Rutgers Cancer Institute, at 2021 ASCO to talk about what she believed was the most interesting and impactful study to come out of the meeting.

Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.

During a discussion at 2021 ASCO, Neal D. Shore, MD, said he was most excited to see data from the phase 3 VISION trial of lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer.

An overview of predictive and prognostic biomarkers used by breast oncologists to aid in adjuvant treatment decisions for HR-positive disease, as outlined by the NCCN guidelines.

Ferdinandos Skoulidis, MD, PhD, MRCP, details what he was most excited to learn about at 2021 ASCO.

The rationale for treating patients with early stage HR-positive breast cancer with extended adjuvant therapy based on lessons learned through clinical trial evidence and real-world practice.

Kathleen Moore, MD, discusses findings compiled from 3 clinical trials of niraparib in patients with ovarian cancer.

Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma.

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

Dr. Daniel Ahn discusses the implications of postoperative ctDNA testing for decision-making in early stage CRC.

Moreau highlighted important updates in the field of multiple myeloma, including the CARTITUDE-1 trial, which yielded promising results with ciltacabtagene autoleucel and read out at the 2021 ASCO Annual Meeting.

Shaji Kumar, MD, talks about 5-year follow-up data regarding the use of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma who are not eligible for transplant.

Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma.

Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer.